These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27518855)

  • 1. [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].
    Pattloch D; Richter A; Manger B; Dockhorn R; Meier L; Tony HP; Zink A; Strangfeld A
    Z Rheumatol; 2017 Apr; 76(3):210-218. PubMed ID: 27518855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
    Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
    Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.
    Baganz L; Richter A; Kekow J; Bussmann A; Krause A; Stille C; Listing J; Zink A; Strangfeld A
    Rheumatol Int; 2018 Apr; 38(4):579-587. PubMed ID: 29143933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI).
    Movahedi M; Joshi R; Rampakakis E; Thorne C; Cesta A; Sampalis JS; Bombardier C;
    Medicine (Baltimore); 2019 May; 98(20):e15517. PubMed ID: 31096451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
    Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
    Gerhold K; Richter A; Schneider M; Bergerhausen HJ; Demary W; Liebhaber A; Listing J; Zink A; Strangfeld A
    Rheumatology (Oxford); 2015 Oct; 54(10):1858-66. PubMed ID: 26001633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
    Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
    Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
    Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
    Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers].
    Albrecht K; Huscher D; Eidner T; Kleinert S; Späthling-Mestekemper S; Bischoff S; Zink A
    Z Rheumatol; 2017 Feb; 76(1):50-57. PubMed ID: 27379740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.
    Pundole X; Zamora NV; Siddhanamatha H; Lin H; Tayar J; Hong LC; Li L; Suarez-Almazor ME
    Clin Rheumatol; 2020 Mar; 39(3):787-794. PubMed ID: 31853733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How frequent are poor prognostic markers in rheumatoid arthritis? : An estimate based on three epidemiologic cohorts].
    Albrecht K; Richter A; Meissner Y; Huscher D; Baganz L; Thiele K; Schneider M; Strangfeld A; Zink A
    Z Rheumatol; 2017 Jun; 76(5):434-442. PubMed ID: 28429118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
    Wilke T; Mueller S; Lee SC; Majer I; Heisen M
    BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.
    Rintelen B; Zwerina J; Herold M; Singer F; Hitzelhammer J; Halder W; Eichbauer-Sturm G; Puchner R; Stetter M; Leeb BF;
    BMC Musculoskelet Disord; 2016 Aug; 17(1):358. PubMed ID: 27550175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
    Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
    Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
    Gabay C; Riek M; Scherer A; Finckh A;
    Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.